Product Code: RP-ID-10352027 |
Published Date: 21 Oct 2022 |
Region: NA |
Category: Healthcare & Pharmaceuticals |
Report ID: 10352027
Market Overview:
Global Diagnostic Testing STDS Market Analysis & Outlook 2030
In 2021, the global diagnostics testing STDS market likely to exceed USD 19 billion. Increasing patient awareness, such as educational activities and growing government initiatives, is expected to drive market growth. In addition, the growing population with multiple temporary sexual partners has also contributed to the growth of the market. It is estimated that during the forecast period, the STD diagnosis industry will see lucrative growth, mainly due to the increasing number of technologically advanced products. In the field of diagnosis, more accurate tests are provided. Result. In addition, the major shift from traditional laboratory testing to rapid and immediate testing has promoted the growth of a series of technologically advanced products, including diagnostic kits, instruments and reagents.
Government reforms aimed at improving healthcare infrastructure, especially in the emerging Asia-Pacific region and MEA countries, are expected to drive the growth of the diagnostics industry for sexually transmitted diseases during the forecast period. Per capita income is the driving force behind the medical reform that supports the development of the STD diagnosis industry. The introduction of new diagnostic methods and the improvement of the testing service infrastructure provide faster and more accurate test results, helping to better treat sexually transmitted diseases.
Type information:
It is estimated that the STD diagnosis industry is experiencing growth, mainly due to the prevalence of various infections, such as chlamydia, syphilis, gonorrhea, herpes simplex virus, human papilloma virus, human immunodeficiency virus, chancroid and other infections, including vaginitis And trichomonal vaginitis. Bacterial STIs include gonorrhea, chlamydia, and syphilis, while viral STIs include genital herpes, HIV, genital warts (HPV), and hepatitis.
The microorganisms that cause sexually transmitted infections are found in blood, semen, and vaginal fluids. Sexually transmitted diseases caused by chlamydia dominate in terms of income and were valued at approximately US$6 billion in 2014. However, the diagnosis of sexually transmitted diseases caused by syphilis is on the rise and is estimated to account for more than 20% of total income. By 2022, due to the rising prevalence of syphilis infections worldwide, it will grow at a healthy compound annual growth rate during the forecast period.
Location of testing knowledge:
The industry is divided into laboratory testing and point-of-care testing according to the testing location. Laboratory testing is a cumbersome but more accurate method involving commercial/private laboratories and public health laboratories. Although point-of-care testing (including test kits) is faster, the results may not be very accurate; however, bedside testing or mobile testing that promotes rapid medical care to patients is occupying a lucrative compound annual growth rate of over 11% market share. Due to the advantages of real-time testing equipment, a major change has taken place from traditional laboratory testing to fast and simple real-time testing.
Test equipment information:
The test equipment used for STD diagnosis is subdivided according to laboratory equipment and real-time testing equipment. Laboratory equipment includes thermal cycler: PCR, lateral flow reader, flow cytometer, differential light scattering machine and absorbance microplate reader: enzyme-linked immunosorbent assay (ELISA). During the forecast period, the CRP used for STD diagnosis is expected to grow at a strong compound annual growth rate of over 8%. The instant detection equipment part includes telephone chips (microfluidics and ICT) and portable/desktop/rapid diagnostic kits. Technological innovations in point-of-care testing equipment bring more accurate and reliable results. By 2022, the portable POC test equipment market is expected to exceed USD19 billion.
Regional information:
The industry is divided into North America, Europe, Asia Pacific, Latin America and MEA by region. The growth of the industry is manifested in the increase in the adoption of technologically advanced products. In addition, the emergence of new POC testing concepts, public health laboratories that provide powerful services for STD testing, and the provision of insurance coverage are driving the growth of the industry during the forecast period. Public health insurance plan to increase people’s health awareness. In addition, the availability of advanced STD test equipment approved by the FDA is driving market growth. The Asia-Pacific regions share in 2020 exceeded 20%. The driving factors include the rising prevalence of sexually transmitted infections in less developed countries in the Asia-Pacific region and the economic boom in these regions that supports the growth of diagnosis of sexually transmitted diseases.
Competitive information:
Major companies operating in the STD diagnostic field include Roche Holdings AG, Abbott Laboratories, Becton Dickinson and Company, Hologic Inc., Danaher Corporation, Affymetrix, bioMerieux, Cepheid Inc., Alere Inc., DiaSorin and Orasure. These companies focus on partnerships and product/technology licensing opportunities in the STD diagnostic industry.
Related Reports
Proof of Quality & Reliability
